Patents by Inventor Weidong Feng

Weidong Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11951778
    Abstract: A sound absorber is configured as a rectangular hexahedral box and forms a porous double-layer Helmholtz resonance sound absorbing structure, at the same time, the sound absorber in the form of a box forms a structural resonance sound absorbing device itself, and the first-order natural mode frequency of the device is identical to that of a wheel air chamber. When the box-type sound absorbing structure is assembled in a wheel, double functions of absorbing acoustic resonance of the wheel air chamber under the organic combination of Helmholtz resonance sound absorption and structural resonance sound absorption can be realized.
    Type: Grant
    Filed: January 19, 2020
    Date of Patent: April 9, 2024
    Assignee: CITIC Dicastal Co., LTD
    Inventors: Shiwen Xu, Mingbo Chen, Minglei Li, Shaobing Huang, Tiefeng Hu, Shuwei Feng, Dadong Wang, Weidong Liu
  • Patent number: 9889123
    Abstract: The invention relates to polymorphs of deuterated omega-diphenylurea or salts thereof. In particular, the invention provides polymorphs of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl)-ureido]-phenoxy}-2-(N-1?,1?,1?-trideutero-methyl)picolinamide or its salt, namely, polymorphs of the compound as shown in formula (I) or its salt. The polymorphs are suited for preparing the pharmaceutical composition used for inhibiting phosphokinase (such as raf kinases).
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: February 13, 2018
    Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.
    Inventor: Weidong Feng
  • Publication number: 20170128427
    Abstract: The invention relates to polymorphs of deuterated omega-diphenylurea or salts thereof. In particular, the invention provides polymorphs of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl)-ureido]-phenoxy}-2-(N-1?,1?,1?-trideutero-methyl)picolinamide or its salt, namely, polymorphs of the compound as shown in formula (I) or its salt. The polymorphs are suited for preparing the pharmaceutical composition used for inhibiting phosphokinase (such as raf kinases).
    Type: Application
    Filed: January 25, 2017
    Publication date: May 11, 2017
    Inventor: Weidong FENG
  • Patent number: 9573900
    Abstract: The invention relates to polymorphs of deuterated omega-diphenylurea or salts thereof. In particular, the invention provides polymorphs of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl)-ureido]-phenoxy}-2-(N-1?,1?,1?-trideutero-methyl)picolinamide or its salt, namely, polymorphs of the compound as shown in formula (I) or its salt. The polymorphs are suited for preparing the pharmaceutical composition used for inhibiting phosphokinase (such as raf kinases).
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: February 21, 2017
    Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.
    Inventor: Weidong Feng
  • Publication number: 20150266823
    Abstract: The invention relates to polymorphs of deuterated omega-diphenylurea or salts thereof. In particular, the invention provides polymorphs of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl)-ureido]-phenoxy}-2-(N-1?,1?,1?-trideutero-methyl)picolinamide or its salt, namely, polymorphs of the compound as shown in formula (I) or its salt. The polymorphs are suited for preparing the pharmaceutical composition used for inhibiting phosphokinase (such as raf kinases).
    Type: Application
    Filed: July 16, 2013
    Publication date: September 24, 2015
    Inventor: Weidong Feng
  • Patent number: 9078933
    Abstract: Methods and processes for preparation and production of deuterated ?-diphenylurea are disclosed. Especially, a kind of deuterated ?-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenyl)-N?-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: July 14, 2015
    Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.
    Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
  • Patent number: 9072796
    Abstract: Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: July 7, 2015
    Assignee: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD.
    Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
  • Publication number: 20150175545
    Abstract: A fluoro-substituted deuterated diphenylurea compound, especially 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-(N-(methyl-d3))picolinamide, preparing method and use for treating or preventing tumor and relative diseases thereof.
    Type: Application
    Filed: March 4, 2015
    Publication date: June 25, 2015
    Inventors: Weidong Feng, Xiaoyong GAO, Xiaojun DAI
  • Patent number: 8759531
    Abstract: A fluoro-substituted deuterated diphenylurea compound, especially 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-(N-(methyl-d3))picolinamide, preparing method and use for treating or preventing tumor and relative diseases thereof.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: June 24, 2014
    Assignee: Suzhou Zelgen Biopharmaccceutical Co., Ltd.
    Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
  • Patent number: 8748666
    Abstract: Preparation methods of methyl-d3-amine and salts thereof are provided, which contain the following steps: (i) nitromethane is subjected to react with deuterium oxide in the present of bases and phase-transfer catalysts to form nitromethane-d3, which is subsequently subjected to reduction in an inert solvent to form methyl-d3-amine, and optionally, methyl-d3-amine reacts subsequently with acids to form salts of methyl-d3-amine; or (ii) N-(1,1,1-trideuteriomethyl)phthalimide is subjected to react with acids to form salts of methyl-d3-amine. The present methods are easy, high efficient, and low cost.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: June 10, 2014
    Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.
    Inventors: Xiaoyong Gao, Weidong Feng, Xiaojun Dai
  • Publication number: 20140128612
    Abstract: Methods and processes for preparation and production of deuterated ?-diphenylurea are disclosed. Especially, a kind of deuterated ?-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenyl)-N?-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 8, 2014
    Applicant: Suzhou Zelgen Biopharmaceutical Co., Ltd.
    Inventors: Weidong FENG, Xiaoyong GAO, Xiaojun DAI
  • Publication number: 20140088311
    Abstract: Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.
    Type: Application
    Filed: November 27, 2013
    Publication date: March 27, 2014
    Applicant: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD.
    Inventors: Weidong FENG, Xiaoyong GAO, Xiaojun DAI
  • Patent number: 8669369
    Abstract: Methods and processes for preparation and production of deuterated ?-diphenylurea are disclosed. Especially, a kind of deuterated ?-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenyl)-N?-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: March 11, 2014
    Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.
    Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
  • Patent number: 8618306
    Abstract: Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: December 31, 2013
    Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.
    Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
  • Publication number: 20130060044
    Abstract: Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.
    Type: Application
    Filed: March 17, 2011
    Publication date: March 7, 2013
    Applicant: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD.
    Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
  • Publication number: 20130060043
    Abstract: A fluoro-substituted deuterated diphenylurea compound, especially 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-(N-(methyl-d3))picolinamide, preparing method and use for treating or preventing tumor and relative diseases thereof.
    Type: Application
    Filed: March 17, 2011
    Publication date: March 7, 2013
    Applicant: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD
    Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
  • Publication number: 20130035492
    Abstract: Methods and processes for preparation and production of deuterated ?-diphenylurea are disclosed. Especially, a kind of deuterated ?-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenye-N?-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.
    Type: Application
    Filed: March 17, 2011
    Publication date: February 7, 2013
    Applicant: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD.
    Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
  • Publication number: 20130018209
    Abstract: Preparation methods of methyl-d3-amine and salts thereof are provided, which contain the following steps: (i) nitromethane is subjected to react with deuterium oxide in the present of bases and phase-transfer catalysts to form nitromethane-d3, which is subsequently subjected to reduction in an inert solvent to form methyl-d3-amine, and optionally, methyl-d3-amine reacts subsequently with acids to form salts of methyl-d3-amine; or (ii) N-(1,1,1-trideuteriomethyl)phthalimide is subjected to react with acids to form salts of methyl-d3-amine. The present methods are easy, high efficient, and low cost.
    Type: Application
    Filed: March 17, 2011
    Publication date: January 17, 2013
    Applicant: Suzhou Zelgen Biopharmaceutical Co., Ltd.
    Inventors: Xiaoyong Gao, Weidong Feng, Xiaojun Dai